Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?

NCT ID NCT07762105

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether adding atorvastatin, a common cholesterol-lowering drug, to the standard steroid treatment can better reduce eye muscle swelling in people with moderate-to-severe thyroid eye disease. Half of the participants will receive the standard steroid alone, while the other half will also take atorvastatin daily for 24 weeks. The study will measure changes in eye muscle size using CT scans and look at certain biological markers to see if the combination therapy is more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atorvastatin (a cholesterol-lowering drug) added to standard intravenous methylprednisolone (a steroid)
What this could lead to
If it works, adding atorvastatin to standard steroid treatment could offer a more effective way to reduce eye muscle swelling and improve symptoms in thyroid eye disease.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. The benefit of atorvastatin for this condition is unproven, and it may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES OPHTHALMOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Universitas Gadjah Mada

    Yogyakarta, Yogyakarta, Indonesia, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.